Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.
Cantargia has raised $13.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Cantargia's investors include Sunstone Life Science Ventures, Fenja Capital, Lubio Science.
Cantargia is headquartered in Lund, Sweden.
Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.
Cantargia is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cantargia — Funding & Investors." VCBacked, May 21, 2026, https://www.vcbacked.co/company/cantargia. Accessed August 16, 2026.
VCBacked. (2026). Cantargia — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/cantargia
{{cite web |title=Cantargia — Funding & Investors |url=https://www.vcbacked.co/company/cantargia |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated